Research programme: biodefence vaccines - Crucell/Naval Medical Research Center

Drug Profile

Research programme: biodefence vaccines - Crucell/Naval Medical Research Center

Alternative Names: Biodefense vaccines - Crucell/Naval Medical Research Center

Latest Information Update: 16 Jun 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Crucell; Naval Medical Research Center
  • Developer Naval Medical Research Center
  • Class Anthrax vaccines; Plague vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Anthrax; Yersinia infections

Most Recent Events

  • 06 Mar 2008 Preclinical development is ongoing
  • 07 Aug 2007 Ichor Medical Systems partners with the Naval Medical Research Center to assess Ichor's TriGrid™ Delivery System in the development of a DNA vaccine for anthrax and plague
  • 01 Sep 2005 Preclinical trials in Anthrax in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top